Pharma industry expert spearheads Achilles’ business growth

9 Nov 2013

Dr. Robert Brooks joins Achilles from Abbott to develop supply chain solutions for pharma

Achilles, a global business leader in supply chain risk evaluation and management, announced today the appointment of Dr. Robert Brooks as Business Development Director for the pharmaceutical and healthcare industries. Robert brings with him a wealth of experience in the pharma industry, previously working as a lead consultant for Abbott and most recently AbbVie.

Robert’s expertise includes health and safety, production, operations, supply chain, logistics and procurement within the pharma industry over a 20-year period. Highlights of his career include delivering multi million pound projects and programmes for major pharma industry companies, as well as working in global roles for Abbott at divisional and corporate level. With his extensive experience and knowledge of the sector, Robert will be the driving force behind Achilles’ growing presence in the pharmaceutical field.

His appointment comes at a time when the industry faces a number of supply chain challenges such as bribery allegations and counterfeit drugs as well as on-going geo-political and environmental issues and consumers and regulators demanding higher standards and compliance.

Robert said: “I’m thrilled to be joining Achilles in a role that brings a collaborative approach to supply chain risk evaluation and management for the pharmaceutical and healthcare industries – and I look forward to putting my professional passion into bringing value to the sector and its wider community. My background helping manage complex supply chains and risks will further support Achilles’ clients who are facing similar challenges. I’m excited about what the future holds for the pharmaceutical industry and truly feel that Achilles will add value not yet available in the industry.”

Adrian Chamberlain, CEO of Achilles, comments: “We are delighted to appoint someone of Robert’s calibre to join our business as we seek to realise our ambitious growth plans in pharma.”


Share


Get great insights in your inbox every month

Subscribe